Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.

ABSTRACT:

Background

Patients with heart failure and preserved ejection fraction (HFpEF) have a poor prognosis, and no therapies have been proven to improve outcomes. It has been proposed that heart failure, including HFpEF, represents overlapping syndromes that may have different prognoses. We present an exploratory study of patients enrolled in the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) using latent class analysis (LCA) with validation using the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved study to identify HFpEF subgroups.

Methods and results

In total, 4113 HFpEF patients randomized to irbesartan or placebo were characterized according to 11 clinical features. The HFpEF subgroups were ide

SUBMITTER: Kao DP 

PROVIDER: S-EPMC4654630 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature